WO2015166040A3 - Chalcone derivatives and their use in treating cancer - Google Patents

Chalcone derivatives and their use in treating cancer Download PDF

Info

Publication number
WO2015166040A3
WO2015166040A3 PCT/EP2015/059500 EP2015059500W WO2015166040A3 WO 2015166040 A3 WO2015166040 A3 WO 2015166040A3 EP 2015059500 W EP2015059500 W EP 2015059500W WO 2015166040 A3 WO2015166040 A3 WO 2015166040A3
Authority
WO
WIPO (PCT)
Prior art keywords
aryl
treating cancer
cancer
heteroaryl
aliphatic
Prior art date
Application number
PCT/EP2015/059500
Other languages
French (fr)
Other versions
WO2015166040A2 (en
Inventor
Bhabatosh Chaudhuri
Original Assignee
De Montfort University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by De Montfort University filed Critical De Montfort University
Publication of WO2015166040A2 publication Critical patent/WO2015166040A2/en
Publication of WO2015166040A3 publication Critical patent/WO2015166040A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/46—Oxygen atoms
    • C07D213/50—Ketonic radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present application relates to a compound of formula (I) for use in the prevention or treatment of cancer, wherein rings A and B are independently an aryl or a heteroaryl, wherein the aryl and/or the heteroaryl are optionally substituted with one or more substitutents selected from the group consisting of aliphatic, alkoxy, thioalkyl, alkylamino, halogen, hydroxy, cyano, nitro, hydroxyalkyl, alkylcarbonyloxy, alkoxycarbonyl, alkylcarbonyl, haloalkyl, alkylsulfonylamino NH2, NO2, SO2RX, SORX and COORX, where RX is hydrogen, aliphatic or aryl. The compounds are particularly provided for the prevention and/or treatment of cancer of the lung, colon, pancreas, liver and/or kidney.
PCT/EP2015/059500 2014-05-01 2015-04-30 Compound WO2015166040A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1407693.9 2014-05-01
GBGB1407693.9A GB201407693D0 (en) 2014-05-01 2014-05-01 Compound

Publications (2)

Publication Number Publication Date
WO2015166040A2 WO2015166040A2 (en) 2015-11-05
WO2015166040A3 true WO2015166040A3 (en) 2016-01-14

Family

ID=50980424

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2015/059500 WO2015166040A2 (en) 2014-05-01 2015-04-30 Compound

Country Status (2)

Country Link
GB (1) GB201407693D0 (en)
WO (1) WO2015166040A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109535068B (en) * 2018-12-26 2022-07-29 中国药科大学 Pyridine substituted chalcone compound or pharmaceutically acceptable salt thereof, and preparation method and application thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096753A (en) * 1996-12-05 2000-08-01 Amgen Inc. Substituted pyrimidinone and pyridone compounds and methods of use
WO2008069608A1 (en) * 2006-12-07 2008-06-12 Seoul Nationaluniversity Industry Foundation Method for screening anti-cancer compounds inhibiting function of tm4sf5 and anti-cancer composition containing chalcone compounds
WO2008156783A2 (en) * 2007-06-18 2008-12-24 University Of Louisville Research Foundation, Inc. Family of pfkfb3 inhibitors with anti-neoplastic activities
WO2013054998A1 (en) * 2011-10-13 2013-04-18 건국대학교 산학협력단 Novel chalcone derivative and anticancer composition comprising same as active ingredient

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096753A (en) * 1996-12-05 2000-08-01 Amgen Inc. Substituted pyrimidinone and pyridone compounds and methods of use
WO2008069608A1 (en) * 2006-12-07 2008-06-12 Seoul Nationaluniversity Industry Foundation Method for screening anti-cancer compounds inhibiting function of tm4sf5 and anti-cancer composition containing chalcone compounds
WO2008156783A2 (en) * 2007-06-18 2008-12-24 University Of Louisville Research Foundation, Inc. Family of pfkfb3 inhibitors with anti-neoplastic activities
WO2013054998A1 (en) * 2011-10-13 2013-04-18 건국대학교 산학협력단 Novel chalcone derivative and anticancer composition comprising same as active ingredient

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
DONNELLY D. ET AL.: "SYNTHESIS OF HETEROCYCLIC-SUBSTITUTED CHROMONES AND RELATED COMPOUNDS AS POTENTIAL ANTICANCER AGENTS", JOURNAL OF MEDICINAL CHEMISTRY, vol. 8, no. 6, 1965, pages 872 - 875, XP002750970 *
EDWARDS M.L. ET AL.: "CHALCONES: A NEW CLASS OF ANTIMITOTIC AGENTS", JOURNAL OF MEDICINAL CHEMISTRY, vol. 33, 1990, pages 1948 - 1954, XP002750969 *
KOK WAI LAM ET AL.: "SYNTHESIS AND QSAR ANALYSIS OF CHALCONE DERIVATIVES AS NITRIC OXIDE INHIBITORY AGENT", MED. CHEM. RES., vol. 21, 2012, pages 1953 - 1966, XP002742648 *
LASTERRA-SANCHEZ ET AL.: "DEVELOPEMENT OF THE JULIA ASYMETRIC EPOXIDATION REACTION. PART 1. APPLICATION OF THE OXIDATION TO ENONES OTHER THAN CHALCONES", J. CHEM. SOC., vol. 1, 1 January 1996 (1996-01-01), pages 343 - 348, XP002742645 *
MARVEL ET AL.: "PYRIDINE ANALOGS OF CHALCONE AND THEIR POLYMERIZATION REACTIONS", JOURNAL OF ORGANIC CHEMISTRY, vol. 20, no. 12, 1955, pages 1785 - 1792, XP002742646 *
PATHI SUMAN ET AL.: "MICROWAVE-ASSISTED CONVENIENT SYNTHESIS OF ALPHA-BETA-UNSATURATED ESTERS AND KETONES VIA ALDOL-ADDUCT ELIMINATION", HELVETICA CHIMICA ACTA, vol. 96, 2013, pages 1548 - 1559, XP002750967 *
SHINJI YAMADA ET AL.: "CATION -PI CONTROLLED SOLID-STATE PHOTODIMERIZATION OF 4-AZACHALCONES", JACS, vol. 131, 2009, pages 2098 - 2099, XP002742647 *
ULLAH A. ET AL.: "COMBINATORIAL SYNTHESIS, LEAD IDENTIFICATION AND ANTITUMOR STUDY OF A CHALCONE-BASED POSITIONAL-SCANNING LIBRARY", CHEMISTRY AND BIODIVERSITY, vol. 4, 2007, pages 203 - 214, XP002750968 *
VIEWEG U A H: "Synthese neuer heterocyclisch substituierter 2-Thioxo-1,2-dihydro-pyridin-3-carbonitrile", DIE PHARMAZIE, vol. 44, no. 9, 1 January 1989 (1989-01-01), GOVI VERLAG PHARMAZEUTISCHER VERLAG GMBH, ESCHBORN, DE, pages 639 - 640, XP001526717, ISSN: 0031-7144 *

Also Published As

Publication number Publication date
GB201407693D0 (en) 2014-06-18
WO2015166040A2 (en) 2015-11-05

Similar Documents

Publication Publication Date Title
PH12019501443A1 (en) Benzooxazole derivatives as immunomodulators
PH12018502710A1 (en) Heterocyclic compounds as immunomodulators
PH12018501084A1 (en) Heterocyclic compounds as immunomodulators
MX2022005290A (en) Heterocyclic compounds as immunomodulators.
WO2017075629A3 (en) Wee 1 kinase inhibitors and methods of making and using the same
MX2021014531A (en) Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith.
PH12016500055A1 (en) N,6-bis(aryl or heteroaryl)-1,3,5-triazine-2,4-diamine compounds as idh2 mutants inhibitors for the treatment of cancer
MX2018002402A (en) Bicyclic-fused heteroaryl or aryl compounds as irak4 modulators.
PH12018500987A1 (en) Dihydroimidazopyrazinone derivatives useful in the treatment of cancer
GEP20217211B (en) Substituted carbonucleoside derivatives useful as anticancer agents
WO2016161410A3 (en) Treatment of cancer using inhibitors of tgf-beta and pd-1
MD20170016A2 (en) Aminopyrimidinyl compounds as JAK inhibitors
MY198613A (en) Nitrobenzyl derivatives of anti-cancer agents
MX2016002544A (en) Compounds useful as immunomodulators.
WO2014164704A3 (en) Compounds and compositions for the treatment of cancer
UA113470C2 (en) PIRIMIDINE AND PORIDINE COMPOUNDS AND THEIR APPLICATIONS
EA033238B1 (en) New thienopyrimidine derivatives as nik inhibitors
WO2017027359A8 (en) Pyridines and their use in the treatment of cancer
EP3448522A4 (en) Novel substituted imidazopyridine compounds as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan-2,3-dioxygenase
MX368767B (en) (5,6-dihydro)pyrimido[4,5-e]indolizines.
EP3500257A4 (en) Kinase inhibitor compounds, compositions, and methods of treating cancer
EA201692550A1 (en) COMPOUNDS CONTAINING THE SYSTEM 1,1 ', 2,5'-TETRAGIDROSPIRO [INDOL-3,2'-PYRROL] -2,5'-DIONA AS ANTIBITANT INHIBITORS OF PEL-Protein Interaction
TN2018000090A1 (en) New imidazo[4,5-b]pyridine derivatives as dual dyrk1/clk1 inhibitors
WO2016016728A3 (en) Bcl-3 inhibitors
EA201891240A1 (en) 1,3,4-TIADIAZOLIC COMPOUNDS AND THEIR APPLICATION IN THE TREATMENT OF CANCER

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15722959

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15722959

Country of ref document: EP

Kind code of ref document: A2